Home
>
US Stocks
>
Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (ALNY)

$188.67

+3.66

(+1.98%)▲

Market is closed - opens 7 PM, 02 Jun 2023

Insights on Alnylam Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 335.03M → 319.29M (in $), with an average decrease of 4.7% per quarter

Performance

  • $184.07
    $189.58
    $188.67
    downward going graph

    2.44%

    Downside

    Day's Volatility :2.9%

    Upside

    0.48%

    downward going graph
  • $120.43
    $242.97
    $188.67
    downward going graph

    36.17%

    Downside

    52 Weeks Volatility :50.43%

    Upside

    22.35%

    downward going graph

Returns

PeriodAlnylam Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-2.97%
0.7%
-7.0%
6 Months
-19.51%
-7.9%
-6.5%
1 Year
50.33%
-2.0%
-6.8%
3 Years
35.91%
25.4%
24.7%

Highlights

Market Capitalization
23.2B
Book Value
- $2.09
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-8.81
PEG Ratio
-0.49
Wall Street Target Price
247.87
Profit Margin
-93.13%
Operating Margin TTM
-68.93%
Return On Assets TTM
-14.43%
Return On Equity TTM
-1500.66%
Revenue TTM
1.1B
Revenue Per Share TTM
9.32
Quarterly Revenue Growth YOY
49.7%
Gross Profit TTM
868.6M
EBITDA
-739.1M
Diluted Eps TTM
-8.81
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.16
EPS Estimate Next Year
-2.46
EPS Estimate Current Quarter
-1.76
EPS Estimate Next Quarter
-1.66

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 33 Wall street analysts offering stock ratings for Alnylam Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 33 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
24
23
22
Hold
9
9
10
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 31.38%

Current $188.67
Target $247.87

Company Financials

FY17Y/Y Change
Revenue
89.9M
↑ 90.66%
Net Income
-490.9M
↑ 19.69%
Net Profit Margin
-545.95%
↑ 323.68%
FY18Y/Y Change
Revenue
74.9M
↓ 16.69%
Net Income
-761.5M
↑ 55.13%
Net Profit Margin
-1.0K%
↓ 470.63%
FY19Y/Y Change
Revenue
219.8M
↑ 193.36%
Net Income
-886.1M
↑ 16.37%
Net Profit Margin
-403.24%
↑ 613.34%
FY20Y/Y Change
Revenue
492.9M
↑ 124.28%
Net Income
-858.3M
↓ 3.14%
Net Profit Margin
-174.15%
↑ 229.09%
FY21Y/Y Change
Revenue
844.3M
↑ 71.31%
Net Income
-852.8M
↓ 0.64%
Net Profit Margin
-101.01%
↑ 73.14%
FY22Y/Y Change
Revenue
1.0B
↑ 22.88%
Net Income
-1.1B
↑ 32.64%
Net Profit Margin
-109.04%
↓ 8.03%
Q4 FY21Q/Q Change
Revenue
258.5M
↑ 37.79%
Net Income
-258.5M
↑ 26.38%
Net Profit Margin
-99.97%
↑ 9.03%
Q1 FY22Q/Q Change
Revenue
213.3M
↓ 17.51%
Net Income
-240.3M
↓ 7.01%
Net Profit Margin
-112.7%
↓ 12.73%
Q2 FY22Q/Q Change
Revenue
224.8M
↑ 5.42%
Net Income
-277.4M
↑ 15.42%
Net Profit Margin
-123.39%
↓ 10.69%
Q3 FY22Q/Q Change
Revenue
264.3M
↑ 17.56%
Net Income
-405.9M
↑ 46.33%
Net Profit Margin
-153.58%
↓ 30.19%
Q4 FY22Q/Q Change
Revenue
335.0M
↑ 26.76%
Net Income
-207.5M
↓ 48.88%
Net Profit Margin
-61.93%
↑ 91.65%
Q1 FY23Q/Q Change
Revenue
319.3M
↓ 4.7%
Net Income
-170.6M
↓ 17.77%
Net Profit Margin
-53.44%
↑ 8.49%
FY17Y/Y Change
Total Assets
2.0B
↑ 57.96%
Total Liabilities
228.3M
↓ 33.36%
FY18Y/Y Change
Total Assets
1.6B
↓ 21.05%
Total Liabilities
272.8M
↑ 19.51%
FY19Y/Y Change
Total Assets
2.4B
↑ 52.09%
Total Liabilities
956.4M
↑ 250.55%
FY20Y/Y Change
Total Assets
3.4B
↑ 42.25%
Total Liabilities
2.4B
↑ 149.97%
FY21Y/Y Change
Total Assets
3.6B
↑ 6.93%
Total Liabilities
3.1B
↑ 27.78%
FY22Y/Y Change
Total Assets
3.5B
↓ 2.66%
Total Liabilities
3.7B
↑ 21.26%
Q4 FY21Q/Q Change
Total Assets
3.6B
↑ 4.92%
Total Liabilities
3.1B
↑ 12.47%
Q1 FY22Q/Q Change
Total Assets
3.4B
↓ 5.76%
Total Liabilities
3.0B
↓ 0.74%
Q2 FY22Q/Q Change
Total Assets
3.3B
↓ 3.0%
Total Liabilities
3.2B
↑ 4.02%
Q3 FY22Q/Q Change
Total Assets
3.5B
↑ 6.15%
Total Liabilities
3.6B
↑ 14.22%
Q4 FY22Q/Q Change
Total Assets
3.5B
↑ 0.31%
Total Liabilities
3.7B
↑ 2.82%
Q1 FY23Q/Q Change
Total Assets
3.4B
↓ 4.35%
Total Liabilities
3.7B
↓ 1.44%
FY17Y/Y Change
Operating Cash Flow
-382.8M
↑ 24.4%
Investing Cash Flow
-290.4M
↓ 303.63%
Financing Cash Flow
1.1B
↑ 532.56%
FY18Y/Y Change
Operating Cash Flow
-562.6M
↑ 46.98%
Investing Cash Flow
272.9M
↓ 194.0%
Financing Cash Flow
65.5M
↓ 94.18%
FY19Y/Y Change
Operating Cash Flow
-278.4M
↓ 50.51%
Investing Cash Flow
-417.7M
↓ 253.03%
Financing Cash Flow
823.2M
↑ 1157.35%
FY20Y/Y Change
Operating Cash Flow
-615.0M
↑ 120.87%
Investing Cash Flow
-435.5M
↑ 4.27%
Financing Cash Flow
995.0M
↑ 20.87%
FY21Y/Y Change
Operating Cash Flow
-641.7M
↑ 4.35%
Investing Cash Flow
-273.3M
↓ 37.25%
Financing Cash Flow
1.2B
↑ 25.34%
Q4 FY21Q/Q Change
Operating Cash Flow
-150.1M
↑ 12.02%
Investing Cash Flow
-413.4M
↑ 368.34%
Financing Cash Flow
292.3M
↓ 49.06%
Q1 FY22Q/Q Change
Operating Cash Flow
-171.2M
↑ 14.02%
Investing Cash Flow
-147.4M
↓ 64.34%
Financing Cash Flow
35.0M
↓ 88.04%
Q2 FY22Q/Q Change
Operating Cash Flow
-122.8M
↓ 28.26%
Investing Cash Flow
142.8M
↓ 196.86%
Financing Cash Flow
30.3M
↓ 13.21%
Q3 FY22Q/Q Change
Operating Cash Flow
-115.3M
↓ 6.14%
Investing Cash Flow
313.9M
↑ 119.82%
Financing Cash Flow
297.0M
↑ 879.08%

Technicals Summary

Sell

Neutral

Buy

Alnylam Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-7.04%
-19.51%
50.33%
35.91%
86.8%
Moderna, Inc.
Moderna, Inc.
-2.19%
-29.52%
-8.32%
114.67%
590.97%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.43%
-4.6%
15.93%
18.38%
134.28%
Seagen, Inc.
Seagen, Inc.
-2.63%
59.03%
43.99%
21.05%
216.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.48%
0.7%
19.84%
13.84%
116.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-6.16
-15.01
-0.14
0.0
-2.09
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$23.2B
86.8%
NA
-93.13%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
590.97%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
134.28%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
216.49%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
116.25%
26.18
35.4%

Institutional Holdings

  • Capital World Investors

    13.23%

  • FMR Inc

    10.85%

  • Vanguard Group Inc

    9.32%

  • Baillie Gifford & Co Limited.

    6.94%

  • BlackRock Inc

    6.82%

  • Wellington Management Company LLP

    5.01%

Corporate Announcements

  • Alnylam Pharmaceuticals, Inc. Earnings

    Alnylam Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.

Organization
Alnylam Pharmaceuticals, Inc.
Employees
2002
CEO
Mr. Michael W. Bonney B.A.
Industry
Health Technology

Discover More

FAQs